Levazeo SR 75 Tablet contains Levosulpiride 75 mg, a selective dopamine D2 receptor antagonist primarily used for the treatment of gastrointestinal disorders and certain psychiatric conditions. Levosulpiride exhibits prokinetic and antiemetic properties by enhancing gastric motility and accelerating gastric emptying, making it effective in managing functional dyspepsia, gastroesophageal reflux disease (GERD), and delayed gastric emptying. Additionally, Levosulpiride has antipsychotic and antidepressant effects due to its modulation of dopaminergic pathways, which may be beneficial in treating schizophrenia, depression, and anxiety disorders. The sustained-release (SR) formulation ensures a controlled and prolonged release of the active ingredient, providing consistent therapeutic plasma levels and improving patient compliance by reducing dosing frequency. Levazeo SR 75 is generally well-tolerated; however, potential side effects include extrapyramidal symptoms, hyperprolactinemia, and gastrointestinal disturbances. It should be used cautiously in patients with a history of seizures, renal or hepatic impairment, and those on concomitant medications affecting dopamine pathways. Levazeo SR 75 Tablet should be prescribed and administered under medical supervision, with dosage adjustments based on clinical response and tolerability. Regular monitoring is recommended to optimize therapeutic outcomes and minimize adverse effects.